Key Takeaways & Executive Findings
- •• Comprehensive overview of pharmacovigilance systems and their evolution. • Integration of toxicological assessments enhances drug safety monitoring. • Real-world data and AI are transforming signal detection and risk assessment. • Global harmonization and data sharing are critical for effective pharmacovigilance.
Abstract
Pharmacovigilance and toxicology are critical disciplines in ensuring drug safety and public health. This comprehensive review synthesizes current practices, regulatory frameworks, and emerging trends in pharmacovigilance, with a focus on the integration of toxicological assessments. We discuss the evolution of pharmacovigilance systems, the role of real-world data, and the challenges of adverse drug reaction reporting. The review highlights the importance of a multidisciplinary approach, incorporating clinical, epidemiological, and toxicological perspectives to enhance drug safety monitoring. Key findings include the need for improved data sharing, the adoption of artificial intelligence in signal detection, and the harmonization of global regulatory standards. This paper provides a roadmap for future research and policy development in pharmacovigilance and toxicology.
1. Introduction
Pharmacovigilance, defined as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems, has become a cornerstone of public health. The thalidomide tragedy in the 1960s catalyzed the establishment of systematic drug safety monitoring systems worldwide. Since then, pharmacovigilance has evolved from a reactive reporting system to a proactive, science-based discipline that integrates toxicological data to predict and prevent adverse drug reactions.
This review aims to provide a comprehensive overview of the current state of pharmacovigilance and toxicology, highlighting the challenges and opportunities in the field. We examine the regulatory frameworks, the role of real-world evidence, and the emerging technologies that are shaping the future of drug safety. By synthesizing recent literature and expert insights, we propose a roadmap for enhancing pharmacovigilance practices, with an emphasis on the integration of toxicological assessments to improve patient outcomes.
Loading authentic research manuscript (Pages 1–5)...
John Smith, Jane Doe, Robert Johnson (2026). Pharmacovigilance and Toxicology: A Comprehensive Review of Current Practices and Future Directions. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-00001-2
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is pharmacovigilance?
Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. It is essential for ensuring the safety of medicines throughout their lifecycle.
Why is toxicology important in pharmacovigilance?
Toxicology provides critical insights into the mechanisms of drug toxicity, helping to predict and prevent adverse reactions. Integrating toxicological data into pharmacovigilance enhances the ability to assess risk and improve drug safety.
How is real-world data used in pharmacovigilance?
Real-world data, such as electronic health records and patient registries, are increasingly used to complement clinical trial data. They provide valuable information on drug safety in diverse populations and real-world settings, improving signal detection and risk assessment.
What role does artificial intelligence play in pharmacovigilance?
Artificial intelligence, particularly machine learning, is being used to analyze large datasets for signal detection, predict adverse drug reactions, and automate reporting processes. AI can enhance the efficiency and accuracy of pharmacovigilance activities.
What are the challenges in global pharmacovigilance?
Challenges include underreporting of adverse drug reactions, lack of harmonization across regulatory frameworks, data privacy concerns, and limited resources in low- and middle-income countries. Addressing these requires international collaboration and investment in pharmacovigilance infrastructure.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.